RxDoctor Payments Data

Erica Horstman, DO

Family Medicine · Seminole, FLNPI 1801177563

Payments from drug & device makers

$709in general payments, 2019–2025

Across 37 payments — averaging $19.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$150
  • AbbVie$141
  • Lilly USA, LLC$122
  • Johnson & Johnson$75
  • Dexcom, Inc.$51
  • Novo Nordisk$42
  • plus $127 from 6 others

What the payments were for

  • Food & beverage$709100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GSK8$150
AbbVie7$141
Lilly USA, LLC6$122
Johnson & Johnson4$75
Dexcom, Inc.3$51
Novo Nordisk2$42
Pfizer2$40
Bayer1$27
AstraZeneca1$19
TMS Neurohealth Centers Inc.1$15
Idorsia Pharmaceuticals US Inc1$14
Boston Scientific1$12

How this compares

$709 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$27,631
Medicare patients
95
Services billed
336

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban38$44,207
Trelegy ElliptaFluticasone/Umeclidin/Vilanter36$36,780
XareltoRivaroxaban27$35,411
JanuviaSitagliptin Phosphate21$31,769
OzempicSemaglutide17$17,556
MyrbetriqMirabegron18$16,046
Stiolto RespimatTiotropium Br/Olodaterol Hcl11$15,868
Gabapentin163$5,318
Celecoxib29$5,064
SymbicortBudesonide/Formoterol Fumarate12$4,883
Albuterol Sulfate HfaAlbuterol Sulfate177$4,761
Fluticasone-SalmeterolFluticasone Propion/Salmeterol11$3,375
Oxybutynin Chloride72$2,967
Atorvastatin Calcium348$2,596
Duloxetine Hcl43$2,518

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$40$44,20738 claims
GSKTrelegy Ellipta, Arnuity Ellipta$150$39,18648 claims
Johnson & JohnsonXarelto$75$35,41127 claims
Novo NordiskOzempic$42$17,55617 claims
AstraZenecaSymbicort$19$4,88312 claims
AbbVieSynthroid$141$2,27638 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Seminole

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →